Association between dynapenic obesity and risk of cardiovascular disease: The Hisayama study
- PMID: 39378156
- PMCID: PMC11634510
- DOI: 10.1002/jcsm.13564
Association between dynapenic obesity and risk of cardiovascular disease: The Hisayama study
Abstract
Background: Dynapenic obesity is a condition characterized by high adiposity levels combined with muscle dysfunction. Although high adiposity and muscle loss/dysfunction are thought to synergistically increase the risk of cardiovascular disease (CVD), few studies have addressed the association between dynapenic and sarcopenic obesity and CVD. We aimed to investigate the association of dynapenic obesity with incident CVD events using the data from a population-based prospective longitudinal study in Japan.
Methods: A total of 2490 community-dwelling Japanese aged 40-79 years (42.5% males, mean age 57.7 ± 10.6 years) without a history of CVD were followed up for a median of 24 years. Handgrip strength was classified as low, medium, or high by age- and sex-specific tertiles. Body mass index (BMI) levels were categorized as lean (<18.5 kg/m2), normal (18.5-24.9 kg/m2), or obese (≥25.0 kg/m2). Dynapenic obesity was defined as having both low handgrip strength and obesity. The outcomes were defined as the first-ever development of CVD (defined as stroke or coronary heart disease). The hazard ratios (HRs) and their 95% confidence intervals (CIs) for the development of CVD were estimated using a Cox proportional hazards model, in which participants with high handgrip strength and normal BMI were used as a reference group. Mediation analyses used serum high-sensitivity C-reactive protein (hs-CRP) and homeostatic model assessment for insulin resistance (HOMA-IR) as mediators.
Results: During the follow-up period, 482 participants developed CVD events (324 cases of stroke and 209 of coronary heart disease). The multivariable-adjusted risk of CVD increased significantly among participants with dynapenic obesity compared with the reference group (HR 1.49, 95% CI 1.03-2.17). An analysis by age groups showed a further increase in the risk of CVD among participants with dynapenic obesity aged less than 65 years (HR 1.66, 95% CI 1.04-2.65). In mediation analyses for participants aged less than 65 years, serum hs-CRP was shown to be a significant mediator explaining 13.8% of the association between dynapenic obesity and the development of CVD, while HOMA-IR explained 12.2% of this relationship.
Conclusions: Dynapenic obesity was a significant risk factor for the development of CVD in a general Japanese population. This association was more pronounced among those aged <65 years. Inflammation, and possibly glucose metabolism, might partly mediate this association. Our findings suggest that preventing muscle dysfunction as well as appropriate weight control, especially in middle-age, are important for preventing the development of CVD.
Keywords: Body mass index; Cardiovascular disease; Dynapenic obesity; Handgrip strength.
© 2024 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
Conflict of interest statement
All authors declare that they have no conflicts of interest.
Figures
References
-
- Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–307. - PubMed
-
- Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231–243. - PubMed
MeSH terms
Grants and funding
- JP22K07421/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JP22K17396/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JP23K09692/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JP23K09717/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JP23K06787/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JP23K09060/Ministry of Education, Culture, Sports, Science and Technology of Japan
- JPMH23FA1006/Ministry of Health, Labour and Welfare of Japan
- JPMH23FA1022/Ministry of Health, Labour and Welfare of Japan
- JPMH24GB1002/Ministry of Health, Labour and Welfare of Japan
- JP24dk0207053/Japan Agency for Medical Research and Development
- JP24km0405209/Japan Agency for Medical Research and Development
- JP24tm0524003/Japan Agency for Medical Research and Development
- JPMJPF2210/Japan Science and Technology Agency
- Eli Lilly Japan K.K.
- JOA-SubsidizedScienceProjectResearch2022-2/Japanese Orthopaedic Association
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
